More on TAK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $17.76 |
|
|||
| Open | $17.79 | ||||
| 52 Wk High | $0.55 | ||||
| 52 Wk Low | $0.55 | ||||
| Day High | $17.88 | ||||
| Day Low | $17.71 | ||||
| P/E | N/A | ||||
| EPS | $-0.20 | ||||
| Volume | 2,310,143 | ||||
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 02
- FDA accepts rusfertide application with priority review for blood disorder
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,900 at JPMorgan
- Takeda reports positive pediatric trial results for ENTYVIO ulcerative colitis treatment
- Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- Form 6-K TAKEDA PHARMACEUTICAL For: Feb 10
- FDA accepts Takeda drug application for narcolepsy treatment
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,800 at CLSA
Entities mentioned with TAK
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Dividend | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
